Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bristol-Myers Squibb Company (BMY) Citi Annual Global Healthcare Conference 2025 December 4, 2025 9:00 AM EST
Company Participants
Adam Lenkowsky – Executive VP & Chief Commercialization Officer
David Elkins – Executive VP & CFO
Conference Call Participants
Geoffrey Meacham – Citigroup Inc., Research Division
Presentation
Geoffrey Meacham
Citigroup Inc., Research Division
Geoff Meacham. I’m the senior biopharma analyst. And we’re thrilled today to have Bristol-Myers with us on stage. We have CFO, David Elkins. We also have Adam Lenkowsky, Head of Commercial. So guys, welcome.
Unknown Executive
Good to be here. Thanks for having us.
Geoffrey Meacham
Citigroup Inc., Research Division
Well, we have a number of questions to go over, partly finance, partly commercial. But maybe for you guys, let’s just talk about yesterday’s news with respect to the Cobenfy study. That’s probably the more topical thing to give us some context for kind of the trial amendments.
Question-and-Answer Session
Adam Lenkowsky
Executive VP & Chief Commercialization Officer
Yes, happy to do that, Geoff. So as you’re aware, yesterday, we announced that the ADEPT-2 study would continue, and we would enroll additional patients into the study. If we take a step back, if you remember, on our Q2 earnings call, we talked about conducting clinical trial site reviews across a number of our near-term priority studies. And as a result of those clinical trial reviews, we did find some irregularities as it relates to the ADEPT-2 study. So we then immediately reported that to the data monitoring committee as well as to the FDA. And in consultation with the FDA and the DMC, the decision was made then to exclude a number of sites and all of those respective patients from the study.
The second area was, again, an agreement with FDA and the DMC was to conduct an interim analysis looking
